杨林承,祖凌云,高炜

• 1:北京大学第三医院心内科卫生部心血管分子生物学与调节肽重点实验室分子心血管学教育部重点实验室心血管受体研究北京市重点实验室

摘要(Abstract)：

<正>1前蛋白转化酶枯草溶菌素9(PCSK9)概述PCSK9既往又被称为神经细胞凋亡调节转化酶(neural apoptosis-regulated convertase-1,NARC-1),于2003年由Seidah等[1]首次发现,为蛋白转化酶(proprotein convertase,PC)家族的第9个成员。人类PCSK9基因定位于1p32,长度约22 kb,包含12个外显子及1个内含子,编码由692个氨基酸组成的糖蛋白,该糖蛋白含有信号肽、前结构域、枯草杆

关键词(KeyWords)： 前蛋白转化酶枯草溶菌素9;基因突变;冠心病

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 杨林承,祖凌云,高炜

参考文献(References)：

• [1]Seidah NG,Benjannet S,Wickham L,et al.The secretory proprotein convertase neural apoptosis-regulated convertase 1(NARC-1):liver regeneration and neuronal differentiation.Proc Natl Acad Sci U S A,2003,100(3):928-933.
• [2]Henrich S,Lindberg I,Bode W,et al.Proprotein convertase models based on the crystal structures of furin and kexin:explanation of their specifi city.J Mol Biol,2005,345(2):211-227.
• [3]Mc Nutt MC,Lagace TA,Horton JD.Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in Hep G2 cells.J Biol Chem,2007,282(29):20799-20803.
• [4]Benjannet S,Rhainds D,Essalmani R,et al.NARC-1/PCSK9 and its natural mutants:zymogen cleavage and effects on the low density lipoprotein(LDL)receptor and LDL cholesterol.J Biol Chem,2004,279(47):48865-48875.
• [5]Anderson ED,Molloy SS,Jean F,et al.The ordered and compartment-specf if ic autoproteolytic removal of the f urin intramolecular chaperone is required for enzyme activation.J Biol Chem,2002,277(15):12879-12890.
• [6]Naureckiene S,Ma L,Sreekumar K,et al.Functional characterization of Narc 1,a novel proteinase related to proteinase K.Arch Biochem Biophys,2003,420(1):55-67.
• [7]Zaid A,Roubtsova A,Essalmani R,et al.Proprotein convertase subtilisin/kexin type 9(PCSK9):hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.Hepatology,2008,48(2):646-654.
• [8]Rudenko G,Henry L,Henderson K,et al.Structure of the LDLreceptor extracellular domain at endosomal p H.Science,2002,298(5602):2353-2358.
• [9]Yamamoto T,Lu C,Ryan RO.A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor.J Biol Chem,2011,286(7):5464-5470.
• [10]Lakoski SG,Lagace TA,Cohen JC,et al.Genetic and metabolic determinants of plasma PCSK9 levels.J Clin Endocrinol Metab,2009,94(7):2537-2543.
• [11]Persson L,Henriksson P,Westerlund E,et al.Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a)or bile acid synthesis in women.Arterioscler Thromb Vasc Biol,2012,32(3):810-814.
• [12]Mbikay M,Sirois F,Mayne J,et al.PCSK9-defi cient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.FEBSLett,2010,584(4):701-706.
• [13]Schulz R,Schluter KD,Laufs U.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9(PCSK9).Basic Res Cardiol,2015,110(2):4.
• [14]Abifadel M,Varret M,Rabes JP,et al.Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.Nat Genet,2003,34(2):154-156.
• [15]Cunningham D,Danley DE,Geoghegan KF,et al.Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.Nat Struct Mol Biol,2007,14(5):413-419.
• [16]Benjannet S,Rhainds D,Hamelin J,et al.The proprotein convertase(PC)PCSK9 is inactivated by furin and/or PC5/6A:functional consequences of natural mutations and post-translational modifi cations.J Biol Chem,2006,281(41):30561-30572.
• [17]Cohen J,Pertsemlidis A,Kotowski IK,et al.Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.Nat Genet,2005,37(2):161-165.
• [18]Cameron J,Holla?L,Laerdahl JK,et al.Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage.Atherosclerosis,2009,203(1):161-165.
• [19]Leigh SE,Leren TP,Humphries SE.Commentary PCSK9 variants:A new database.Atherosclerosis,2009,203(1):32-33.
• [20]Blesa S,Vernia S,Garcia-Garcia AB,et al.A new PCSK9 gene promoter variant affects gene expression and causes autosomal dominant hypercholesterolemia.J Clin Endocrinol Metab,2008,93(9):3577-3583.
• [21]Shioji K,Mannami T,Kokubo Y,et al.Genetic variants in PCSK9affect the cholesterol level in Japanese.J Hum Genet,2004,49(2):109-114.
• [22]Miyake Y,Kimura R,Kokubo Y,et al.Genetic variants in PCSK9in the Japanese population:rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population.Atherosclerosis,2008,196(1):29-36.
• [23]Kotowski IK,Pertsemlidis A,Luke A,et al.A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.Am J Hum Genet,2006,78(3):410-422.
• [24]Fasano T,Cefalu AB,Di Leo E,et al.A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma lowdensity lipoprotein cholesterol.Arterioscler Thromb Vasc Biol,2007,27(3):677-681.
• [25]Zhao Z,Tuakli-Wosornu Y,Lagace TA,et al.Molecular characterization of loss-of-f unction mutations in PCSK9 and identification of a compound heterozygote.Am J Hum Genet,2006,79(3):514-523.
• [26]Berge KE,Ose L,Leren TP.Missense mutations in the PCSK9gene are associated with hypocholesterolemia and possibly increased response to statin therapy.Arterioscler Thromb Vasc Biol,2006,26(5):1094-1100.
• [27]Homer VM,Marais AD,Charlton F,et al.Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.Atherosclerosis,2008,196(2):659-666.
• [28]Cameron J,Holla OL,Laerdahl JK,et al.Characterization of novel mutations in the catalytic domain of the PCSK9 gene.J Intern Med,2008,263(4):420-431.
• [29]Allard D,Amsellem S,Abifadel M,et al.Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.Hum Mutat,2005,26(5):497.
• [30]Timms KM,Wagner S,Samuels ME,et al.A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree.Hum Genet,2004,114(4):349-353.
• [31]Bourbon M,Alves AC,Medeiros AM,et al.Familial hypercholesterolaemia in Portugal.Atherosclerosis,2008,196(2):633-642.
• [32]Dubuc G,Tremblay M,Pare G,et al.A new method for measurement of total plasma PCSK9:clinical applications.J Lipid Res,2010,51(1):140-149.
• [33]Pisciotta L,Priore Oliva C,Cefalu AB,et al.Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia.Atherosclerosis,2006,186(2):433-440.
• [34]Chen SN,Ballantyne CM,Gotto AM Jr,et al.A common PCSK9 haplotype,encompassing the E670G coding single nucleotide polymorphism,is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.J Am Coll Cardiol,2005,45(10):1611-1619.
• [35]den Dunnen JT,Antonarakis SE.Nomenclature for the description of human sequence variations.Hum Genet,2001,109(1):121-124.
• [36]Stranger BE,Forrest MS,Dunning M,et al.Relative impact of nucleotide and copy number variation on gene expression phenotypes.Science,2007,315(5813):848-853.
• [37]Shahid SU,Shabana,Cooper JA,et al.Genetic risk analysis of coronary artery disease in Pakistani subjects using a genetic risk score of 21 variants.Atherosclerosis,2017,258:1-7.
• [38]Cohen JC,Boerwinkle E,Mosley TH,Jr,et al.Sequence variations in PCSK9,low LDL,and protection against coronary heart disease.N Engl J Med,2006,354(12):1264-1272.
• [39]Benn M,Nordestgaard BG,Grande P,et al.PCSK9 R46L,lowdensity lipoprotein cholesterol levels,and risk of ischemic heart disease:3 independent studies and meta-analyses.J Am Coll Cardiol,2010,55(25):2833-2842.
• [40]Qiu C,Zeng P,Li X,et al.What is the impact of PCSK9rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk:a meta-analysis.Lipids Health Dis,2017,16(1):111.
• [41]Polisecki E,Peter I,Robertson M,et al.Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels,but does not significantly lower vascular disease risk in an elderly population.Atherosclerosis,2008,200(1):95-101.
• [42]Guella I,Asselta R,Ardissino D,et al.Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population.J Lipid Res,2010,51(11):3342-3349.
• [43]Naoumova RP,Tosi I,Patel D,et al.Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene:long-term follow-up and treatment response.Arterioscler Thromb Vasc Biol,2005,25(12):2654-2660.
• [44]Kathiresan S,Voight BF,Purcell S,,et al.Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants.Nat Genet,2009,41(3):334-341.
• [45]Hus LA,Teng MS,Ko YL,et al.The PCSK9 gene E670Gpolymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan.Clin Chem Lab Med,2009,47(2):154-158.
• [46]Aung LH,Yin RX,Miao L,et al.The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations.Lipids Health Dis,2011,10:5.
• [47]Sabatine MS,Giugliano RP,Keech AC,et al.Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.N Engl JMed,2017,376(18):1713-1722.